A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Caribou Biosciences, Inc. data from phase 1 ANTLER study is expected in 1H 2025. Click here to find out why I'm neutral on ...

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

Brookline raised the firm’s price target on Caribou Biosciences (CRBU) to $34 from $26 and keeps a Buy rating on the shares. Caribou plans to ...

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...